
    
      This is a phase I, open-label, single-dose in healthy subjects conducted at single center.The
      objectives are to evaluate the metabolic and safety profile of EXPARELÂ®. Each volunteer will
      receive one dose of the investigational drug via subcutaneous injection at multiple points
      during the study period. Study duration is around 54 days, including screening, confinement,
      ambulatory visit and a phone follow up.
    
  